Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy

Shang Yi Tai; Yang Jie; Li Lei; Li Xiao Jiang

Article Contents

Article Navigation > Journal of Kunming Medical University > 2017 > 38(07): 80-84

Shang Yi Tai , Yang Jie , Li Lei , Li Xiao Jiang . Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy[J]. Journal of Kunming Medical University, 2017, 38(07): 80-84.

Citation:

Shang Yi Tai , Yang Jie , Li Lei , Li Xiao Jiang . Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy[J]. Journal of Kunming Medical University, 2017, 38(07): 80-84.

Citation:

Shang Yi Tai , Yang Jie , Li Lei , Li Xiao Jiang . Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy[J]. Journal of Kunming Medical University, 2017, 38(07): 80-84.

PDF( 197 KB)

Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy

Funds:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (2014FZ037);

Received Date: 2017-03-14

Abstract

Abstract

Objective To analyze the therapeutic efficacy of chemoradiotherapy combined with recombinant human vascular endostatin (endostar) in the treatment of locally advanced head and neck squamous cell carcinoma.Methods From July 2011 to June 2014, data of the patients with locally advanced head and neck squamous cell carcinomas were collected, including 46 patients with chemoradiotherapy combined with endostar and 45 patients with chemoradiotherapy only and the two groups were divided: endostar groups (46 patients) and control group (45 patients) . Objective response rates, disease control rate, overall survival (OS) , and progress free survival (PFS) were compared. Quality of Life Questionnaire from University of Washington was applied to evaluate the life quality of the two groups. Results The objective response rate of endostar group and control group were 87.0% and 75.6% respectively (χ2=1.946, P>0.05) , disease control rate being 97.8% and 95.6% respectively (χ2=0.368, P>0.05) , the median PFS being 18.7 months and 14.7 months respectively (P<0.05) , and median OS being 26.8 months and 23.6 months respectively (P>0.05) . The adverse reaction rate were similar between the two groups. The scores of quality of life, including mood and anxiety domain and total score, in endostar group were higher than those in control group (P <0.05) . Conclusion Endostar combined with chemoradiotherapy can enhance the therapeutic effect of locally advanced head and neck squamous cell carcinoma, prolong free survival progress, improve the quality of life and does not increase adverse reaction rate. But the survival benefit for patients still needs further study.
- Head and Neck Neoplasms,
- Angiogenesis Inhibitors,
- Endostatin

FullText(HTML)

References(12)

References

[1]	[1]FERLAY J, SHIN H R, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (12) :2893-2917.
[2]	[2]SEIWERT T Y, SALAMA J K, VOKES E E.The chemoradiation paradigm in head and neck cancer[J].Nat Clin Pract Oncol, 2007, 4 (3) :156-171.
[3]曹素杰, 张育红.头颈部鳞癌切除患者近期生活质量的影响因素[J].现代肿瘤医学, 2016, 24 (2) :219-221.
[4]	[4]FOLKMAN J.Tumor angiogenesis:Therapeutrc implication[J].N End J Med, 1971, 285 (21) :1182-1187.
[5]	[5]NEUCHRIST C, EROVIC B M, HANDISURYA A, et al.Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck[J].Laryngoscope, 2001, 111 (10) :1834-1841.
[6]	[6]NEUCHRIST C, EROVIC BM, HANDISURYA A, et al.Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck[J].Head Neck, 2003, 25 (6) :464-474.
[7]	[7]RIEDEL F, GOTTE K, LI M, et al.Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo[J].Int J Oncol, 2003, 23 (3) :577-583.
[8]	[8] KIM Y M, HWANG S, KIM Y M, et al.Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1[J].JBC, 2002, 277 (31) :27872-27879.
[9]	[9]WEN Y E, RANYI LIU, CHANGCHUAN PAN, et al.multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J].Mol Ther, 2014, 22 (6) :1221-1229.
[10]	[10]FURY M G, LEE N Y, SHERMAN E, et al.A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer[J].Cancer, 2012, 118 (20) :5008-5014.
[11]	[11]MA X, YAO Y, YUAN D, et al.Recombinant human endostatinendostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One, 2012, 7 (12) :e53449.
[12]牛牛, 李宝兰, 刘朝阳, 等.重组人血管内皮抑制素联合贝伐珠单抗体内抑瘤作用的效果及分析[J].中国肺癌杂志, 2013, 16 (02) :61-66.

Relative Articles(20)

Relative Articles

[1]	Fan WANG, Rong ZENG, Mao ZHANG, Yi REN, Hao DING. Disease Spectrum Analysis of Oral Cavity and Throat Malignant Tumors in the First People’s Hospital of Yunnan Province from 2012 to 2021Epidemiological Analysis of Head and Neck Malignant Tumors in a Hospital from 2012 to 2021. Journal of Kunming Medical University, 2025, 46(11): 1-12.
[2]	Meng LI, Ben NIU, Jin HU, Yanlin MA. Clinical Studies on Thyroid Dysfunction Caused by Immune Checkpoint Inhibitors in Tumor Patients. Journal of Kunming Medical University, 2024, 45(1): 67-72. doi: 10.12259/j.issn.2095-610X.S20240111
[3]	Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527
[4]	Jiang Dong Hui , Chen Yu Lian , Yang Xi , He Xiao Guang , Li Yu Xiao . . Journal of Kunming Medical University, 2020, 41(08): 111-115.
[5]	Chen Xin , Bi Shan , Li Guo Ping . . Journal of Kunming Medical University, 2020, 41(07): 170-174.
[6]	Lin Yi Lin , Zhang Hong , Ding Xiao Xue . . Journal of Kunming Medical University, 2019, 40(05): 1-4.
[7]	Gong Wei , Guo Xin Kui , Wang Huai Jie , Zhou Xiao Qing , Liu Qiang . Clinical Research of Absolute Ethanol Sclerotherapy for Arteriovenous Malformations in the Head and Neck. Journal of Kunming Medical University, 2018, 39(07): 119-123.
[8]	Li Li , Wang Jia , Du Juan , Ke Ting Yu . Research Progress of the Relationship between Arginase Inhibitors and Diabetic Vascular Endothelial Function. Journal of Kunming Medical University, 2018, 39(02): 120-123.
[9]	Feng Lin Sen , Li Jing Juan , Wang Yu Feng . A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer. Journal of Kunming Medical University, 2017, 38(06): 118-123.
[10]	Wang Zhi Qiang , Li Rong Qing , Zhang Yong . Progress in Research of Adaptive Radiation Therapy for Head and Heck Cancer. Journal of Kunming Medical University, 2016, 37(12): 131-134.
[11]	Song Xin Huan . . Journal of Kunming Medical University,
[12]	Gu Wan Gang . . Journal of Kunming Medical University,
[13]	Gu Wan Gang . . Journal of Kunming Medical University,
[14]	Gu Wan Gang . . Journal of Kunming Medical University,
[15]	Sun Zhi Min . . Journal of Kunming Medical University,
[16]	Sun Zhi Min . . Journal of Kunming Medical University,
[17]	Wu Zhi Ping . . Journal of Kunming Medical University,
[18]	Li Lei . . Journal of Kunming Medical University,
[19]	Yang Li Hua . . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,